CoChat

Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis

Open access
Reutrakul, Sirimon, Wroblewski, Kristen, Brown, Rebecca L. · 2012 · Journal of Diabetes Science and Technology

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

The use of U-500 regular insulin (U-500R) to treat diabetic patients with severe insulin resistance has increased. In this review, we performed a meta-analysis of PubMed studies reporting the use of U-500R to evaluate the effects of U-500R on hemoglobin A1c (HbA1c), body weight, and total daily insulin dose (TDD). These studies included 310 patients using U-500R as multiple daily injections (MDI) and 55 patients using U-500R via continuous subcutaneous insulin infusion (CSII). Overall, the use of U-500R as MDI resulted in a significant HbA1c reduction of 1.59%, a significant weight gain of 4.38 kg, and a significant increase in TDD by 51.9 units. The use of U-500R via CSII resulted in a similarly significant HbA1c reduction of 1.64% but a nonsignificant weight gain and a nonsignificant change in TDD. The use of U-500 regular insulin both as MDI and via CSII was not reported to be associated with severe hypoglycemia but was associated with an increase in patient satisfaction as well as in cost savings. Suggestions in initiating U-500R in the outpatient setting using U-500R in hospitalized patients are reviewed. In addition, precautions for avoiding prescription and patient errors are discussed.

Overview

Integrity signals

Registry

Crossref · 10.1177/193229681200600229

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 6

  1. Khan M, 2007, Diabetes., 569, P-1294
  2. Khan M, 2009, Diabetes., 58, PO-2333
  3. Garg R, 2004, Diabetologia., 47, A58
  4. Boldo A, 2011, Endocr Pract., 1
  5. Ziesmer AE, 2011, Endocr Pract., 1
  6. U.S. Food and Drug Administration., 2012, MAUDE Adverse Event Report.

Cited by

See all 94

Metadata

Authors
Reutrakul, S., Wroblewski, K., & Brown, R. L.
Affiliations
  • Rush University Medical Center (US)
  • University of Chicago (US)
Corresponding author
Reutrakul, Sirimon
Venue
Journal of Diabetes Science and Technology
Published
2012-03
Volume
6
Issue
2
Pages
412-420
ISSN
1932-2968 (ISSN-L)
OpenAlex
W2142265157
Cited by
94
References
38
Citations by year
2026: 1 · 2024: 2 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 16 · 2015: 11 · 2014: 15 · 2013: 7
FWCI
1.46
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Diabetes Science and Technology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Center for Research Resources (UL1RR024999)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin resistance, type 2 diabetes, glycemic control, HbA1c, weight gain, total daily insulin dose, multiple daily insulin injections, insulin pump therapy, hypoglycemia, patient satisfaction, cost reduction, prescribing errors, patient education
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Insulin Resistance, Risk Factors, Biomarkers, Weight Gain, Drug Costs, Treatment Outcome, Cost Savings, Patient Satisfaction, Infusions, Subcutaneous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis. https://app.cochat.ai/papers/10.1177/193229681200600229
The paper
Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012). Clinical Use of U-500 Regular Insulin: Review and Meta-Analysis. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229681200600229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.